Some people are facing delays in filling prescriptions for the glucose sensor. Abbott expects to resolve the problem soon.

Abbott (NYSE:ABT) faces a proposed class action lawsuit related to alleged tracking tools used with its FreeStyle Libre ...

Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device ...

Roche will roll out its Accu-Chek Smartguide in the Netherlands, Switzerland and Germany. The company hopes to stand out from competitors with features to predict hypoglycemia.

Among the many corporations that pay a dividend, some do so unpredictably and irregularly. Others rarely raise their payouts ...

Perhaps none is more important than its continuous glucose monitoring (CGM) franchise, the FreeStyle Libre. It has been its best-performing device for years, but as Abbott reported earlier this ...

Perhaps none is more important than its continuous glucose monitoring (CGM) franchise, the FreeStyle Libre. It has been its ... Before you buy stock in Abbott Laboratories, consider this: The ...

Johnny Greig / GettyImages The purchase mortgage market is the portion of the primary mortgage market devoted to loans for new home purchases. The remainder of the primary market comprises ...

Abbott Diabetes Care, Inc. is recalling its FreeStyle Libre 3 sensors after finding a small number of the sensors may provide incorrect high glucose readings, which, if undetected may pose ...

Q2 earnings demonstrate strong financial performance, indicating robust growth and profitability. Capital efficiency metrics highlight the company's effective use of resources to generate returns ...

ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who ...

The announcement comes just after Dexcom, another diabetes company, released its own consumer-friendly sensor. Here's what to ...